Syndax Pharmaceuticals Inc 8K

Syndax Pharmaceuticals reported strong second quarter 2026 revenue growth from Revuforj and Niktimvo, detailed broad pipeline progress, but remained loss-making while affirming guidance and sufficient liquidity to reach profitability.

On August 4, 2026, Syndax Pharmaceuticals, Inc. reported its financial results for the quarter ended June 30, 2026, highlighting a 92% year-over-year increase in total revenue to approximately $72.8 million driven by strong net product sales of Revuforj (revumenib) and collaboration revenue from Niktimvo (axatilimab-csfr), along with updates on its expanding clinical and R&D pipeline, including multiple ongoing and planned Phase 2 and Phase 3 trials, new pipeline assets SNDX-4321 and SNDX-62122, continued operating losses, and guidance that its current cash balance of $575.1 million plus expected revenues should enable the company to reach profitability.

Filing Facts

CIK

1395937

Ticker

SNDX

Form

8K

Source Type

fda

Accession

0001193125-26-332736

Alert Tier

6